Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

June 27, 2000; 54 (12) Article

A 5-month, randomized, placebo-controlled trial of galantamine in AD

P.N. Tariot, P.R. Solomon, J.C. Morris, P. Kershaw, S. Lilienfeld, C. Ding, the Galantamine USA- Study Group
First published June 27, 2000, DOI: https://doi.org/10.1212/WNL.54.12.2269
P.N. Tariot
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.R. Solomon
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.C. Morris
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Kershaw
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Lilienfeld
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
FCP (Neuro)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Ding
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
From the Department of Psychiatry (Dr. Tariot)University of Rochester Medical Center, NY; Department of Psychology (Dr. Solomon), Williams College, MA, and the Memory Clinic, Southwestern Vermont Medical Center, Bennington, VT; Department of Neurology (Dr. Morris), Washington University School of Medicine, St. Louis, MO; the Janssen Research Foundation (Drs. Kershaw and Ding), Titusville, NJ; and the Janssen Research Foundation (Dr. Lilienfeld), Beerse, Belgium.
Full PDF
Citation
A 5-month, randomized, placebo-controlled trial of galantamine in AD
P.N. Tariot, P.R. Solomon, J.C. Morris, P. Kershaw, S. Lilienfeld, C. Ding, the Galantamine USA- Study Group
Neurology Jun 2000, 54 (12) 2269-2276; DOI: 10.1212/WNL.54.12.2269

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2585

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To investigate the efficacy and tolerability of galantamine, using a slow dose escalation schedule of up to 8 weeks, in 978 patients with mild to moderate AD.

Methods: A 5-month multicenter, placebo-controlled, double-blind trial. Following a 4-week placebo run-in, patients were randomized to one of four treatment arms: placebo or galantamine escalated to final maintenance doses of 8, 16, or 24 mg/day. Outcome measures included the cognitive subscale of the AD Assessment Scale (ADAS-cog), the Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), the AD Cooperative Study Activities of Daily Living inventory, and the Neuropsychiatric Inventory. Standard safety evaluations and adverse event monitoring were carried out.

Results: After 5 months, the galantamine–placebo differences on ADAS-cog were 3.3 points for the 16 mg/day group and 3.6 points for the 24 mg/day group (p < 0.001 versus placebo, both doses). Compared with placebo, the galantamine 16- and 24-mg/day groups also had a significantly better outcome on CIBIC-plus, activities of daily living, and behavioral symptoms. Treatment discontinuations due to adverse events were low in all galantamine groups (6 to 10%) and comparable with the discontinuation rate in the placebo group (7%). The incidence of adverse events in the galantamine groups, notably gastrointestinal symptoms, was low and most adverse events were mild.

Conclusions: Galantamine 16 and 24 mg/day significantly benefits the cognitive, functional, and behavioral symptoms of AD as compared with placebo. Slow dose escalation appears to enhance the tolerability of galantamine, minimizing the incidence and severity of adverse events.

  • Received December 14, 1999.
  • Accepted in final form March 17, 2000.
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Appendix
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Hastening the Diagnosis of Amyotrophic Lateral Sclerosis

Dr. Brian Callaghan and Dr. Kellen Quigg

► Watch

Related Articles

  • Galantamine in ADA 6-month randomized, placebo-controlled trial with a 6-month extension

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
    John C. Morris, Pamela A. Cyrus, John Orazem et al.
    Neurology, May 01, 1998
  • Articles
    Galantamine in AD
    A 6-month randomized, placebo-controlled trial with a 6-month extension
    M.A. Raskind, E.R. Peskind, T. Wessel et al.
    Neurology, June 27, 2000
  • Articles
    Metrifonate treatment of the cognitive deficits of Alzheimer's disease
    J. L. Cummings, P. A. Cyrus, F. Bieber et al.
    Neurology, May 01, 1998
  • Articles
    Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L. Cummings, Eugene Schneider, Pierre N. Tariot et al.
    Neurology, July 10, 2006
Neurology: 101 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise